| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1Department of Nephrology and Center of Cardiovascular Research, Charité Campus Mitte, Humboldt University, Berlin, Germany; 2Department of Pediatrics, Second University Hospital, Sun Yat-sen University, Guangzhou, People’s Republic of China; and 3Department of Cell Biology and Institute of Nephrology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
Submitted 12 May 2005 ; accepted in final form 22 July 2005
cGMP serves as the main second messenger of nitric oxide (NO). Antifibrotic effects of enhancing renal cGMP levels have recently been documented in experimental acute anti-Thy-1 glomerulonephritis. The present study compares the effects of the cGMP production-increasing soluble guanylate cyclase (sGC) stimulator BAY 41-2272 with those of the cGMP degradation-limiting phosphodiesterase inhibitor pentoxifylline (PTX) in a progressive model of renal fibrosis. At 1 wk after induction of anti-Thy-1-induced chronic glomerulosclerosis (cGS), rats were randomly assigned to groups as follows: cGS, cGS + BAY 41-2272 (10 mg·kg body wt–1·day–1), or cGS + PTX (50 mg·kg body wt–1·day–1). BAY 41-2272 and PTX reduced systolic blood pressure significantly. At 16 wk, tubulointerstitial expressions of sGC mRNA and NO-induced cGMP synthesis were increased in untreated cGS animals, whereas their glomerular activity was depressed compared with normal controls. Tubulointerstitial and glomerular cGMP production in response to NO were significantly enhanced in animals treated with BAY 41-2272, but not in those treated with PTX. BAY 41-2272 administration resulted in marked reductions of glomerular and tubulointerstitial histological matrix accumulation, expression of TGF-
1 and fibronectin, macrophage infiltration, and cell proliferation as well as improved renal function. In contrast, only moderate and nonsignificant renoprotective changes were observed in the cGS + PTX group. In conclusion, increasing renal cGMP production through BAY 41-2272 significantly improved renal NO-cGMP signaling and limited progression in anti-Thy-1-induced chronic renal fibrosis, whereas inhibition of cGMP degradation by PTX was only moderately effective. The findings indicate that pharmacological enhancement of renal cGMP levels by sGC stimulation represents a novel and effective antifibrotic approach in progressive kidney disorders.
BAY 41-2272; pentoxifylline; TGF-1; progression
This article has been cited by other articles:
|
|
 |
|
  P. Duann and E. A. Lianos GEC-targeted HO-1 expression reduces proteinuria in glomerular immune injury Am J Physiol Renal Physiol, September 1, 2009; 297(3): F629 - F638. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Laws, R. A. Cornford-Nairn, N. Irwin, R. Johnsen, S. Fletcher, S. D. Wilton, and A. J. Hoey Long-term administration of antisense oligonucleotides into the paraspinal muscles of mdx mice reduces kyphosis J Appl Physiol, August 1, 2008; 105(2): 662 - 668. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Lin, C.-F. Cheng, H.-H. Hou, W.-S. Lian, Y.-C. Chao, Y.-Y. Ciou, B. Djoko, M.-T. Tsai, C.-J. Cheng, and R.-B. Yang Disruption of Guanylyl Cyclase-G Protects against Acute Renal Injury J. Am. Soc. Nephrol., February 1, 2008; 19(2): 339 - 348. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Boor, K. Sebekova, T. Ostendorf, and J. Floege Treatment targets in renal fibrosis Nephrol. Dial. Transplant., December 1, 2007; 22(12): 3391 - 3407. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Huang, F. Shi, T. Lei, Y. Song, C. L. Hughes, and G. Liu Effect of the Isoflavone Genistein Against Galactose-Induced Cataracts in Rats Experimental Biology and Medicine, January 1, 2007; 232(1): 118 - 125. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
